Profile
Jeannie T.
Lee is the founder of Translate Bio, Inc. (founded in 2011) and Fulcrum Therapeutics, Inc. (founded in 2015).
She is currently the Director at The Genetics Society of America and a Non-Executive Director at GSK Plc (starting in 2024).
Dr. Lee has an undergraduate degree from Harvard University and a doctorate from Perelman School of Medicine.
Jeannie T. Lee active positions
| Companies | Position | Start |
|---|---|---|
| GSK PLC | Director/Board Member | 2024-03-03 |
| The Genetics Society of America | Director/Board Member | - |
Former positions of Jeannie T. Lee
| Companies | Position | End |
|---|---|---|
| TRANSLATE BIO, INC. | Founder | - |
| FULCRUM THERAPEUTICS, INC. | Founder | - |
Training of Jeannie T. Lee
| Harvard University | Undergraduate Degree |
| Perelman School of Medicine | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 2 |
|---|---|
| FULCRUM THERAPEUTICS, INC. | Health Technology |
| GSK PLC | Health Technology |
| Private companies | 2 |
|---|---|
| The Genetics Society of America | |
Translate Bio, Inc.
 Translate Bio, Inc. BiotechnologyHealth Technology Translate Bio, Inc. engages in the research and development of therapeutic drugs. It focuses on developing medicines to treat diseases caused by protein or gene dysfunction. Its lead product candidate, MRT5005 is designed for the treatment of cystic fibrosis. The company was founded by Arthur M. Krieg and Jeannie T. Lee in 2011 and is headquartered in Lexington, MA. | Health Technology |
- Stock Market
- Insiders
- Jeannie T. Lee
